Pediatric Palliative Care Assessment Tools in the Home-Care Setting: Guidelines (Last Updated: Aug 2, 2019)
Project Line:
Reference List
CADTH | Search
Current Filters
No filters applied.
Cancer Immunotherapy After Adjuvant Immunotherapy: Clinical Effectiveness and Guidelines (Last Updated: Aug 1, 2019)
Project Line:
Reference List
Project Status:
Completed
Portable Stroke Detection Devices for Patients with Stroke Symptoms: A Review of Diagnostic Accuracy and Cost-Effectiveness (Last Updated: Aug 7, 2019)
Project Line:
Health Technology Review
Project Status:
Completed
Natriuretic Peptide testing for Monitoring of Oncology Therapy: Clinical Utility, Cost-Effectiveness, and Guidelines (Last Updated: Aug 6, 2019)
Project Line:
Reference List
Project Status:
Completed
Overnight Bags for Adults With Long-Term Indwelling Urinary Catheters: Clinical Effectiveness, Cost-Effectiveness, and Guidelines (Last Updated: Aug 7, 2019)
Project Line:
Reference List
Project Status:
Completed
Interventions for the Diagnosis of Clostridioides Difficile: Clinical Effectiveness and Guidelines (Last Updated: Aug 2, 2019)
Project Line:
Reference List
Project Status:
Completed
Sugammadex for the Reversal of Neuromuscular Blockade in Surgical Patients: A Review of Clinical Effectiveness and Cost-Effectiveness (Last Updated: Aug 6, 2019)
Project Line:
Health Technology Review
tezacaftor/ivacaftor (Symdeko) (Last Updated: Aug 15, 2019)
Project Line:
Reimbursement Review
Project Status:
Not filed
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Symdeko
Manufacturer:
Vertex Pharmaceuticals Canada Inc.
Submission Type:
Non Submission
Indications:
Cystic fibrosis, F508del mutation(s)
eltrombopag (Revolade ) (Last Updated: Aug 15, 2019)
Project Line:
Reimbursement Review
Project Status:
Not filed
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Revolade
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Non Submission
Indications:
Severe aplastic anemia
ibrutinib (Imbruvica) (Last Updated: Aug 15, 2019)
Project Line:
Reimbursement Review
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Imbruvica
Manufacturer:
Janssen Canada Inc.
Submission Type:
Non Submission
Indications:
Chronic graft versus host disease